Denali Therapeutics Inc (NASDAQ:DNLI) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $24.00.
DNLI has been the subject of several analyst reports. Zacks Investment Research lowered shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 17th. ValuEngine upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
Denali Therapeutics opened at $17.77 on Thursday, according to MarketBeat Ratings. Denali Therapeutics has a 12-month low of $14.72 and a 12-month high of $25.79. The stock has a market cap of $1.66 billion and a price-to-earnings ratio of -3.02.
Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Friday, May 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.39). The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $45.00 million. equities research analysts anticipate that Denali Therapeutics will post -0.74 EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. Allianz Asset Management GmbH boosted its holdings in shares of Denali Therapeutics by 18.4% during the first quarter. Allianz Asset Management GmbH now owns 236,290 shares of the company’s stock worth $4,653,000 after purchasing an additional 36,745 shares during the period. Legal & General Group Plc boosted its holdings in shares of Denali Therapeutics by 93,965.5% during the first quarter. Legal & General Group Plc now owns 51,736 shares of the company’s stock worth $1,018,000 after purchasing an additional 51,681 shares during the period. California State Teachers Retirement System purchased a new stake in shares of Denali Therapeutics during the first quarter worth about $484,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Denali Therapeutics during the first quarter worth about $285,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Denali Therapeutics during the first quarter worth about $246,000. Institutional investors own 63.79% of the company’s stock.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.